... interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activationMélanie Kirchmeyer, Meriem Koufany, Sylvie Sebillaud, Patrick Netter, Jean-Yves Jouzeau and ... agonist, BMS-649 (kindly provided by Bristol-MyersSquibb Company, Princeton, NJ, USA), used at 0.3 μM. Selec-tive agonists (kindly provided by Bristol-Myers Squibb Com-pany) of RAR-α (BMS-753), ... Rixensart, Belgium).Assay for synovial fibroblast viabilityCell viability was assessed by the mitochondria-dependentreduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide...